Literature DB >> 12858005

Change in expression of basic fibroblast growth factor mRNA in a pituitary tumor clonal cell line.

Hitomi Fukuro1, Chihiro Mogi, Kotaro Yokoyama, Kinji Inoue.   

Abstract

To study pituitary tumor formation, we used a rat pituitary tumor cell line, MtT/E, which was derived from an estrogen-induced rat prolactinoma. MtT/E cells are known not to produce any pituitary hormone; however, they do produce the Pit-1 protein, which is known to be a common transcription factor in thyrotropes, somatotropes, and mammotropes. Although MtT/E is a clonal cell line, it exhibits two distinct phenotypes, fibroblastic (F-) and epithelial (E-) cells. We obtained subclonal cell lines from MtT/E cells with characters similar to those of F- and E-cells and called them MtT/E-G1 and MtT/E-B3, respectively. To examine tumor formation by these cells, we implanted them into female Fischer rats. One month later, typical pituitary tumors had appeared in MtT/E-B3-implanted rats; however, tumor formation by MtT/E-G1 was delayed. Interestingly, the tumors formed by MtT/E-B3 cells were intensely vascularized. To examine changes in tumor cell morphology, we performed primary culture and found that spindle-shaped cells appeared. These spindle-shaped cells were immunopositive for the Pit-1 protein, which suggests that they originated from MtT/E-B3 cells. Interestingly, reverse transcriptase polymerase chain reaction showed that both tumors and the cells obtained in primary culture expressed basic fibroblast growth factor (bFGF). By contrast, the original MtT/E-B3 cells did not express bFGF. These results suggested that MtT/E-B3 cells show a change in phenotype during tumor formation; that is, epithelial-type cells change into bFGFexpressing fibroblastic cells. These phenomena, especially the appearance of bFGFexpressing cells in tumor tissue, may explain the extensive angiogenesis in the tumors formed by MtT/E-B3 cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12858005     DOI: 10.1385/ep:14:2:145

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  9 in total

Review 1.  The structure and function of folliculo-stellate cells in the anterior pituitary gland.

Authors:  K Inoue; E F Couch; K Takano; S Ogawa
Journal:  Arch Histol Cytol       Date:  1999-08

Review 2.  Signaling and transcriptional mechanisms in pituitary development.

Authors:  J S Dasen; M G Rosenfeld
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

3.  Purification of a fibroblast growth factor from bovine pituitary.

Authors:  D Gospodarowicz
Journal:  J Biol Chem       Date:  1975-04-10       Impact factor: 5.157

4.  Functional role of estrogen in pituitary tumor pathogenesis.

Authors:  Anthony P Heaney; Manory Fernando; Shlomo Melmed
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

5.  Establishment of a series of pituitary clonal cell lines differing in morphology, hormone secretion, and response to estrogen.

Authors:  K Inoue; M Hattori; T Sakai; S Inukai; N Fujimoto; A Ito
Journal:  Endocrinology       Date:  1990-05       Impact factor: 4.736

6.  Animal models of human pituitary tumors.

Authors:  J Trouillas; C Girod
Journal:  Pathol Res Pract       Date:  1988-09       Impact factor: 3.250

7.  Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis.

Authors:  A P Heaney; G A Horwitz; Z Wang; R Singson; S Melmed
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

8.  Is cellular disruption the mechanism of release of basic fibroblast growth factor from anterior pituitary gonadotropes?

Authors:  J E Schechter
Journal:  Tissue Cell       Date:  1992       Impact factor: 2.466

9.  Immunocytochemical localization of basic fibroblast growth factor in the rat pituitary gland.

Authors:  O Amano; Y Yoshitake; K Nishikawa; S Iseki
Journal:  Arch Histol Cytol       Date:  1993-08
  9 in total
  2 in total

Review 1.  Control dominating subclones for managing cancer progression and posttreatment recurrence by subclonal switchboard signal: implication for new therapies.

Authors:  Shengwen Calvin Li; Katherine L Lee; Jane Luo
Journal:  Stem Cells Dev       Date:  2011-11-02       Impact factor: 3.272

2.  Prolactin-releasing Peptide (PrRP) increases prolactin responses to TRH in vitro and in vivo.

Authors:  Carlos Spuch; Yolanda Diz-Chaves; Diego Pérez-Tilve; Mayte Alvarez-Crespo; Federico Mallo
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.